These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 16583461

  • 1. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
    Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M, Lauer UM, Bitzer M.
    Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
    [Abstract] [Full Text] [Related]

  • 2. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H.
    Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [Abstract] [Full Text] [Related]

  • 3. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A, Flahaut M, Bourloud KB, Auderset K, Meier R, Joseph JM, Gross N.
    BMC Cancer; 2006 Aug 24; 6():214. PubMed ID: 16930472
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 6. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.
    Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, Teufel A, Wörns M, Fischer T, Strand S, Lohse AW, Galle PR.
    Oncol Rep; 2006 Jan 15; 15(1):227-30. PubMed ID: 16328060
    [Abstract] [Full Text] [Related]

  • 7. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK, VanOosten RL, Griffith TS.
    Cancer Res; 2006 Jan 01; 66(1):499-507. PubMed ID: 16397266
    [Abstract] [Full Text] [Related]

  • 8. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
    Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA, Mitsiades N.
    Am J Pathol; 2002 Aug 01; 161(2):643-54. PubMed ID: 12163389
    [Abstract] [Full Text] [Related]

  • 9. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC, Huang HH, Lai CY, Lin YJ, Liou JP, Lai MJ, Li YH, Teng CM, Yang CR.
    Oncotarget; 2016 Jan 05; 7(1):402-17. PubMed ID: 26587975
    [Abstract] [Full Text] [Related]

  • 10. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
    Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF.
    Cancer Res; 2004 Oct 01; 64(19):7086-91. PubMed ID: 15466204
    [Abstract] [Full Text] [Related]

  • 11. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S, Horak P, Pribill I, Haller G, Rössler M, Zielinski CC, Pils D, Krainer M.
    Gynecol Oncol; 2004 Jul 01; 94(1):107-14. PubMed ID: 15262127
    [Abstract] [Full Text] [Related]

  • 12. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 13. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK.
    Int J Mol Med; 2005 Dec 15; 16(6):1125-38. PubMed ID: 16273296
    [Abstract] [Full Text] [Related]

  • 14. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL.
    El-Zawahry A, Lu P, White SJ, Voelkel-Johnson C.
    Cancer Gene Ther; 2006 Mar 15; 13(3):281-9. PubMed ID: 16167063
    [Abstract] [Full Text] [Related]

  • 15. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
    Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, Walczak H.
    Hepatology; 2005 Sep 15; 42(3):588-97. PubMed ID: 16037944
    [Abstract] [Full Text] [Related]

  • 16. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand.
    Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS.
    Cancer Res; 2000 Nov 15; 60(22):6259-65. PubMed ID: 11103780
    [Abstract] [Full Text] [Related]

  • 17. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.
    Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151
    [Abstract] [Full Text] [Related]

  • 18. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J.
    J Orthop Res; 2003 Sep 15; 21(5):949-57. PubMed ID: 12919886
    [Abstract] [Full Text] [Related]

  • 19. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5.
    Zhang B, Shan H, Li D, Li ZR, Zhu KS, Jiang ZB, Huang MS.
    Oncol Rep; 2011 Feb 15; 25(2):461-8. PubMed ID: 21152876
    [Abstract] [Full Text] [Related]

  • 20. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
    Lane D, Cartier A, L'Espérance S, Côté M, Rancourt C, Piché A.
    Gynecol Oncol; 2004 Jun 15; 93(3):594-604. PubMed ID: 15196850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.